1 / 19

Acknowledgements

The Relationship Between CMS Quality Indicators and Long-term Outcomes Among Hospitalized Heart Failure Patients Mark Patterson, Ph.D., M.P.H. Post-doctoral Fellow Duke Clinical Research Institute (DCRI). Acknowledgements. Duke Clinical Research Institute (DCRI) Lesley Curtis, Ph.D.

herb
Download Presentation

Acknowledgements

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Relationship Between CMS Quality Indicators and Long-term Outcomes Among Hospitalized Heart Failure PatientsMark Patterson, Ph.D., M.P.H.Post-doctoral FellowDuke Clinical Research Institute (DCRI)

  2. Acknowledgements • Duke Clinical Research Institute (DCRI) • Lesley Curtis, Ph.D. • Adrian Hernandez, M.D. • Bradley Hammill, M.S. • Kevin Schulman, M.D. • Eric Peterson, M.D. • UCLA Medical Center • Gregg Fonarow, M.D. • Funding Sources • Contract with GlaxoSmithKline • Duke CERTs grant (AHRQ grant #U18HS10548)

  3. Pay-for-Performance and Process Measures • Goal of Pay-for-Performance: Encourage providers to follow recommended clinical care by providing financial incentives • Theory: Financial incentives  improve providers’ adherence  improve clinical outcomes • Process Measures: Estimate provider-level adherence to this recommended clinical care

  4. CMS Heart Failure Process Measures • Improving heart failure care remains a priority for CMS • Prevalence = 5 million; Cost = $30 billion • 4 Core Process Measures • Providing discharge instructions • Conducting left ventricular ejection fraction (LVEF) assessment • Prescribing ACE inhibitors or angiotensin receptor blockers at discharge • Providing smoking cessation counseling

  5. Associations between process measures (PM) and mortality • Mixed evidence in regards to the associations between process measures and mortality • Acute coronary syndrome1 • AMI2 • Heart failure3 • No evidence in regards to associations between PM and long-term mortality 1: Peterson et al., JAMA, 2006 2. Bradley et al., JAMA, 2006 3. Fonarow et al., JAMA, 2007

  6. Objective • Measure associations between the 4 current CMS heart-failure process measures and 1-year mortality • H1: Hospital-level process measures will be associated with patient-level mortality

  7. Data Sources • Retrospective cohort study • Matched HF patients within the OPTIMIZE registry with their Medicare Part A claims (2003 – 2004 • OPTIMIZE-HF • Medicare Part A • CMS denominator files • Matched on age, gender, discharge date, and hospital

  8. Participants • Medicare fee-for-service HF patients matched to the OPTIMIZE-HF registry (N=22,483) • Excluding patients who died before discharge • Excluding hospitals with • missing process measures • with less than 25 patients • Final analytic dataset (N=22,451)

  9. Hospital-level single process measures (PM) • Discharge instructions N=15,142 (67%) • LVEF assessment N=20,061 (89%) • ACEI or ARBs at discharge N=5,457 (24%) • Smoking cessation at discharge N=902 (4%) Frequency of PM documentation ------------------------------------------------------------- Number of patients eligible to receive PM

  10. Hospital-level combined process measures • Composite N=22,451 Total number of processes documented ------------------------------------------------------------ Total number of opportunities to perform • Defect-free N=22,451 Proportion of patients within the hospital having documentation for ALL the PM that they were eligible to receive

  11. Outcome and Control Variables • Patient-level Mortality • CMS denominator file • Patient-level controls • Demographics • Comorbities • Clinical measures • Creatinine, weight, blood pressure • Hospital-level volume • Total HF discharges • % HF discharges of total

  12. Statistical Analysis • Cox multivariate regressions • Controlling for demographics, clinical measures, selected co-morbidities, and hospital volume indicators • Accounting for clustering of patients within hospitals • 6 final models • 4 Models for each single PM • 2 Models for each combined PM

  13. Selected Baseline Characteristics (N=22,451)

  14. Hospital PM Adherence Rates (N=178)

  15. Associations between hospital-level process measures and patient mortality

  16. Discussion • Current CMS heart failure process measures (PM) are not associated with 1-year mortality in Medicare beneficiaries diagnosed with HF • Explanation for null findings • Care given at discharge may not affect 1-year mortality • Documentation of care does not capture the intensity or accuracy of care • High variation for PM may prevent ability to detect small changes if they exist

  17. Limitations • Cross-sectional design • Unobserved factors confounding associations • Patient-level • Hospital-level • Documentation of process measure at discharge may not reflect the care given over 1 year

  18. Strengths • First known study to link clinical registry data with CMS data to examine associations between process measures and long-term outcomes • Generalizeable to Medicare fee-for-service heart failure patients1 • Models • Include both patient and hospital-level covariates • Account for clustering 1: Curtis et al., Abstract Proceedings at AHA, 2007

  19. Conclusions & Recommendations • Null findings do not undermine the need to continue providing care that is good clinical practice • Need to more firmly establish link between PM and outcomes before broadly implementing P4P • Improve the accuracy of the measures • Continue evaluating the effects of PM • Within the context of longitudinal data • Using PM with known clinical efficacy

More Related